A nanostructured skin patch to heal chronic wounds

Active Project Grant Awarded Last action

Award ID
R01DK131417
Recipient
Awarding agency
Obligated
$3,954,903

Award facts

Completion date 95% complete
Place of performance
East Lansing, MI 48824, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Chronic nonhealing wounds are debilitating with high morbidity and mortality. IT is widespread and costly to treat (e.g. ~ $15 billion/year for venous leg ulcers in the united states alone). Despite extensive efforts to develop therapeutic strategies for effective treatment of chronic wounds, so far, limited clinical success has been achieved. Currently available devices and products are designed only to target one or more complex impaired cellular and molecular functions in chronic wounds. The increasing clinical significance and medical and social responsibilities to treat and cure chronic skin wounds are driving the demand for development of efficiently designed and fabricated wound-healing devices. A system that not only possesses the physico-mechanical properties of skin, but also corrects or avoids the impaired molecular and cellular machinery of chronic wounds, including angiogenesis, epithelial migration and cell proliferation, unresolved inflammation, and infection, would be a major advance. The proposed research project is aimed to develop a multifunctional patch with a unique capacity to resume bodies' capacity to heal chronic wounds. In this regards, we develop a nanoextrusion approach to fabricate a multifunctional nanofibrous composite patch capable of addressing the main challenges associated with the healing process of chronic wounds, including i) providing a suitable environment in which cells can easily proliferate and form new blood vessels; II) preventing or reducing existing bacterial infection using ferumoxytol nanoparticles with and without protein corona; and III) minimizing unbalanced and prolonged inflammation. We plan to homogeneously incorporate multi-functional biomolecules (e.g., follistatin-like 1, AC2-26, and ferumoxytol nanoparticles) within its fibrous framework to accelerate angiogenesis and cell proliferation, while minimizing the risk of bacterial infection and prolonged inflammation. A wide range of in-vitro and in-vivo therapeutic efficacy of the novel patches will be conducted. For the in-vivo experiments, we use a RAT models of diabetes provided by charles river to probe the therapeutic and antibacterial efficacy of the patch. Involved mechanisms of the cell and immune system interactions with the multifunctional patch will be identified using a wide range of analysis including advanced electron microscopy. This study will pave the way for the development of new tissue engineering scaffolds to improve the body's natural (endogenous) repair mechanisms by redirecting impaired healing pathways, thus providing a unique opportunity to repair and regenerate damaged skin and tissue in a wide range of chronic wounds.

Transactions

Action Obligated Date
Amendment $392,936
Amendment $360,871
Amendment $24,422
Amendment $24,422
Amendment $366,318
Amendment $366,318
Amendment $366,318
Amendment $408,011
Amendment $408,011
Amendment $408,011
Amendment $408,011
Original award $421,254
Show all 12

Subawards

Subrecipient Amount Awarded
South Shore Hospital Inc. The South Shore Health Center for Wound Healing will be the primary site for patient enrollment and wound fluid sample collection. The SSH Center for Wound… $39,284
South Shore Hospital Inc. The South Shore Health Center for Wound Healing will be the primary site for patient enrollment and wound fluid sample collection. The SSH Center for Wound… $38,393
South Shore Hospital Inc. The South Shore Health Center for Wound Healing will be the primary site for patient enrollment and wound fluid sample collection. The SSH Center for Wound… $43,649

Quick answers

Who received award R01DK131417?

R01DK131417 was awarded to Michigan State University by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on February 1, 2022.

How much is award R01DK131417 worth?

$3,954,903 has been obligated on R01DK131417.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login